The combination of FAK and Hsp90 inhibitors generates enhanced anti-cancer activity with reduced cell growth by inducing G2 cell cycle arrest, inhibition of pro-survival signaling, and activation of apoptosis in NSCLC cells. Here, PTK2 is linked to non-small cell lung carcinoma.